Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · regulatory

Cancer Trial Eligibility Expanded in Final FDA Guidance

16 October 2026 · By · Wire by Fusion42

Published

16 October 2026

Topic

regulatory

◆ Sectors

Biotech

◆ Geography

United States

◆ Source

Read at specialtypharmacycontinuum.com →

◆ Verified

Fusion42 · 17 October 2026 · Fusion42 review

The FDA has finalized guidance that expands eligibility criteria for cancer clinical trials, encouraging broader patient inclusion.

This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 15 Oct 2026 and 16 Oct 2026.

◆ ◆ The Wire takeaway

You must adapt your trial recruitment to new inclusive rules set by the FDA expanding who can join cancer trials. This opens access but also raises compliance and protocol design demands this quarter.

◆ Coverage

2 sources · first reported 15 Oct 2026 · latest 16 Oct 2026

◆ Related on Wire

◆ Topics

Biotechcancer-trialsfda-guidanceclinical-trialsregulatory-expansion